1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2020, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.
Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 6, 21, 14, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Oropharyngeal Cancer - Overview
- Oropharyngeal Cancer - Therapeutics Development
- Oropharyngeal Cancer - Therapeutics Assessment
- Oropharyngeal Cancer - Companies Involved in Therapeutics Development
- Oropharyngeal Cancer - Drug Profiles
- Oropharyngeal Cancer - Dormant Projects
- Oropharyngeal Cancer - Discontinued Products
- Oropharyngeal Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Oropharyngeal Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Oropharyngeal Cancer - Pipeline by AbbVie Inc, H2 2020
- Oropharyngeal Cancer - Pipeline by Advaxis Inc, H2 2020
- Oropharyngeal Cancer - Pipeline by AMI Onco Theranostics LLC, H2 2020
- Oropharyngeal Cancer - Pipeline by Anteris Technologies Ltd, H2 2020
- Oropharyngeal Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2020
- Oropharyngeal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2020
- Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H2 2020
- Oropharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2020
- Oropharyngeal Cancer - Pipeline by Biomimetix JV LLC, H2 2020
- Oropharyngeal Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Oropharyngeal Cancer - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2020
- Oropharyngeal Cancer - Pipeline by Dracen Pharmaceuticals Inc, H2 2020
- Oropharyngeal Cancer - Dormant Projects, H2 2020
- Oropharyngeal Cancer - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Oropharyngeal Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Advaxis Inc
- AMI Onco Theranostics LLC
- Anteris Technologies Ltd
- Ascenta Therapeutics Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Biomimetix JV LLC
- Boehringer Ingelheim International GmbH
- Brooklyn ImmunoTherapeutics LLC
- Dracen Pharmaceuticals Inc
- Eisai Co Ltd
- EpicentRx Inc
- Exelixis Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- IMV Inc
- Incyte Corp
- Innate Pharma SA
- ISA Pharmaceuticals BV
- Jiangsu Hengrui Medicine Co Ltd
- Merck & Co Inc
- Merck KGaA
- Moderna Inc
- Ono Pharmaceutical Co Ltd
